10-K: GB Sciences Reports Positive Preclinical Results and Patent Portfolio Growth in Annual 10-K Filing

GB Sciences' annual 10-K filing highlights positive preclinical results across multiple therapeutic programs and a significant increase in their patent portfolio.

Summary

• GB Sciences, a biopharmaceutical research and development company, focuses on plant-inspired medicines.
• The company's subsidiary, GBS Global Biopharma, is developing patented, disease-targeted formulations.
• Their intellectual property portfolio includes eight U.S. and twelve foreign patents issued, with two foreign patents allowed and numerous pending applications.
• The company's AI-enabled drug discovery platform, PhAROS, is being used to identify novel drug candidates.
• GB Sciences has five drug development programs in the preclinical stage, targeting Parkinson's disease, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular issues.
• Preclinical trials have shown positive results for their Parkinson's disease therapy, including establishing dose ranges and demonstrating good tolerability.
• The company is actively seeking development partners to advance their Parkinson's disease treatment into human clinical trials.
• Preclinical studies have also validated their formulations for chronic pain, anxiety, and depression.
• The company is using a lean drug development program, minimizing expenses through strategic partnerships with universities and contract research organizations.
• GB Sciences has incurred net losses of $1,361,677 for the year ended March 31, 2024, and has an accumulated deficit of $110,066,992.
• The company's independent auditors have expressed doubts about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: While the company has made progress in preclinical studies and patent filings, the significant financial losses, going concern doubts, and ineffective internal controls raise serious concerns. The positive developments are overshadowed by the financial instability and operational risks.

Positives

• The company has a growing intellectual property portfolio with numerous patents issued and pending.
• The PhAROS AI platform is a novel approach to drug discovery.
• Positive preclinical results support the viability of multiple therapeutic programs.
• The company is using a lean development program to minimize expenses.
• The company has identified a Contract Research Organization that will perform the required testing to support their IND filing.
• The company has completed a stability study validating the clinical prototypes for their top three performing cannabinoid-containing Parkinson's formulations.

Negatives

• The company has incurred significant losses and has an accumulated deficit of $110,066,992.
• The independent auditors have expressed doubts about the company's ability to continue as a going concern.
• The company has a working capital deficit of $4,992,115.
• The company has limited capital resources and will need to raise additional capital to sustain operations.
• The company's internal controls over financial reporting were deemed not effective.
• The company has a history of operating in the cannabis industry, which is illegal under federal law.

Risks

• The company has a limited operating history, making it difficult to predict future performance.
• The company may not be able to obtain or maintain relationships with strategic partners.
• The company may not be able to raise sufficient capital to fund its operations.
• The company faces intense competition from other biotech and pharmaceutical companies.
• The company's intellectual property may be infringed upon or misappropriated.
• The company's trade secrets may be difficult to protect.
• The company's future success depends on key personnel and their ability to attract and retain qualified employees.
• The company may be subject to litigation, complaints, or enforcement actions.
• The company may have difficulty accessing banking services.
• The company's insurance coverage may be inadequate.
• The company's stock price may be volatile.
• The company's common stock is categorized as penny stock, which may make it more difficult for investors to sell their shares.
• The company does not intend to pay any cash dividends on its common stock.

Future Outlook

The company intends to move its drug development forward towards clinical trials for its proprietary treatments for chronic pain, stress/anxiety, and cytokine release syndrome therapies after PD. The company is also evaluating options for monetizing its proprietary PhAROS drug discovery platform.

Management Comments

• The company's continued success in having our patents granted validates our novel strategy of protecting simplified ratio-controlled mixtures of natural compounds that treat diseases for which there is a great need for more effective therapies.
• Talks with multiple potential licensing partners are ongoing and remain promising to help support the development of our Parkinsons disease therapy.
• The company runs a lean drug development program through GBSGB and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (CROs).

Industry Context

The biotech industry is highly competitive, with many companies developing therapies for similar indications. GB Sciences is focusing on plant-inspired medicines and using AI to differentiate itself. The company is also targeting rare diseases like MCAS to potentially expedite the regulatory approval process.

Comparison to Industry Standards

• GB Sciences is competing with companies like Cara Therapeutics Inc., Corbus Pharmaceuticals Holdings Inc., Zynerba Pharmaceuticals Inc., Tetra Bio-Pharma, Inc., Revive Therapeutics, Inc., Axim Biotechnologies, Inc., and Emerald BioScience, Inc.
• Many of these competitors have greater financial, technical, and human resources than GB Sciences.
• GB Sciences is using a novel approach to drug discovery with its PhAROS platform, which is different from traditional methods used by many competitors.
• The company's focus on plant-based therapies is also a differentiating factor in the market.
• The company's strategy of targeting rare diseases like MCAS is similar to other companies seeking expedited regulatory approvals.
• The company's lean development program is a common strategy for smaller biotech companies to manage costs.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed in 2022 was settled without liability to the Company in April 2023.
• The company may become involved in legal proceedings and claims in the ordinary course of business.

Related Party Transactions

• The company has accounts payable to an entity controlled by a family member of a former executive and to the current CEO for expenses incurred in connection with the business operations of the Company.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and operational challenges.
• Employees may be affected by the company's financial difficulties and potential restructuring.
• Customers and partners may be impacted by the company's ability to continue operations and develop its products.
• Creditors face the risk of non-payment due to the company's financial situation.

Next Steps

• The company will continue to evaluate suitable development partners to assist in preparing its Parkinson's disease therapy for a first-in-human clinical trial.
• The company intends to move its drug development forward towards clinical trials for its proprietary treatments for chronic pain, stress/anxiety, and cytokine release syndrome therapies after PD.
• The company will continue to seek sources of financing to meet its operational needs.
• The company will work to remediate the identified material weaknesses in internal controls over financial reporting.

Key Dates

Keywords

biopharmaceutical, drug discovery, plant-inspired medicines, patents, AI, Parkinson's disease, chronic pain, cytokine release syndrome, preclinical trials, intellectual property, cannabinoid, kava, clinical trials